AMYD-016A

Cpc provides wide range of products which includes amyd-010a. Category: ß-amyloids and related peptides. Contact us for more information.

Cpc provides wide range of products which includes amyd-011a. Category: ß-amyloids and related peptides. Contact us for more information.

Cpc provides wide range of products which includes amyd-012a. Category: ß-amyloids and related peptides. Contact us for more information.

Cpc provides wide range of products which includes amyd-013a. Category: ß-amyloids and related peptides. Contact us for more information.

Cpc provides wide range of products which includes amyd-014a. Category: ß-amyloids and related peptides. Contact us for more information.

Cpc provides wide range of products which includes amyd-015a. Category: ß-amyloids and related peptides. Contact us for more information.

Cpc provides wide range of products which includes amyd-017a. Category: ß-amyloids and related peptides. Contact us for more information.

Cpc provides wide range of products which includes amyd-018a. Category: ß-amyloids and related peptides. Contact us for more information.

Generic API

Chinese peptide co provides wide range of products which includes (asn670,leu671)-amyloid b/a4 protein precursor770 (667-676) 1mg. It belongs to?-amyloids and related peptides category. Contact us for more information.

Chinese peptide co provides wide range of products which includes (cys(bzl)84,glu(obzl)85)-cd4 (81-92) 25mg. It belongs tohiv related peptide category. Contact us for more information.

Chinese peptide co provides wide range of products which includes (cys(bzl)84,glu(obzl)85)-cd4 (81-92) 5mg. It belongs tohiv related peptide category. Contact us for more information.

SAN JOSE, CA., Feb 1, 2021 /CPCNewswire/ — CPC Scientific Inc. is pleased to announce that the Dutch Medicines Evaluation Board (MEB) has completed its technical review of their client’s drug product and formulation process for Terlipressin. The API provided to the client is manufactured at CPC Scientific’s GMP facility. On January 18, 2021, the MEB granted approval of the drug product and will move to the next phase to review product characterization profiles, specifications, and labels in the Netherlands. The MEB is the Dutch regulatory agency responsible for assessing, monitoring, and promoting the proper use of medicines. After final approval, the drug product will be available for sale in the Netherlands and Germany.